Palivizumab is recommended for neonates and infants who are at high risk for severe RSV disease. The American Academy of Pediatrics ([AAP](https://)) provides guidelines on which infants should receive palivizumab. These include:
- Infants born before 29 weeks' gestation. - Infants with chronic lung disease of prematurity. - Infants with significant congenital heart disease. - Certain infants with neuromuscular disorders or immunocompromised conditions.
